**Supplementary Table 5.**

**Dose intensity and number of cycles of treatment in patients with mCRC**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Dose intensity given (%)**  **Median (range)** | **Age 50–69 years**  ***N* = 303** | **Age 70–89 years**  ***N* = 254** | ***P*** | ***P\**** |
| Capecitabine/5-FU | 87 (1–115) | 71 (0–114) | <0.001 | 0.001 |
| Irinotecan | 95 (1–161) | 77 (36–112) | 0.006 | 0.70 |
| Oxaliplatin | 92 (16–154) | 77 (0–113) | <0.001 | 0.001 |
| Bevacizumab | 99 (9–163) | 96 (52–130) | 0.26 | 0.57 |
| Cetuximab | 98 (39–103) | 87 (55–101) | 0.11 | 0.20 |
| **Number of treatment cycles**  **Median (range)** |  |  |  |  |
| Capecitabine | 8 (1–46) | 6.5 (1–53) | 0.40 | - |
| 5-FU | 12 (1–49) | 12 (1–37) | 0.56 | - |
| Irinotecan | 11 (1–49) | 8 (1–41) | 0.06 | - |
| Oxaliplatin | 7 (1–25) | 6 (1–19) | 0.03 | - |
| Bevacizumab | 8 (1–48) | 8.5 (1–33) | 0.61 | - |
| Cetuximab | 8 (1–35) | 8 (1–19) | 0.86 | - |

\*Adjusted for comorbidity and performance status